Non-pharmacological and pharmacological interventions for the reduction or prevention of topographies of behaviours that challenge in people with intellectual disabilities: a systematic review and meta-analysis of randomised controlled trials

Groves, Laura; Jones, Chris; Welham, Alice; Hamilton, Anna; Liew, Ashley; Richards, Caroline

doi:10.1016/s2215-0366(23)00197-9

Cited by 7 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Often, certain antipsychotics, such as risperidone (D2, 5-HT2 and NE alpha 2 receptor antagonist) or aripiprazole (D2 and 5-HT1A receptor partial agonist), can positively impact and reduce behaviour even in the absence of an underlying mental illness (Groves et al, 2023). However, when these medications are not helping, it is quite usual for requests to be made for an increase in medication dose.…”

Section: Autism and Intellectual Disabilitymentioning

confidence: 99%

Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part II

Cortese,

Besag,

Clark

et al. 2024

J Psychopharmacol

View full text Add to dashboard Cite

As Faculty of the British Association for Psychopharmacology course on child and adolescent psychopharmacology, we present here what we deem are the most common pitfalls, and how to avoid them, in child and adolescent psychopharmacology. In this paper, we specifically addressed common pitfalls in the pharmacological treatment of autism and intellectual disability, eating disorders, neuropsychiatric correlates of epilepsy, and psychosis. Pitfalls in relation to the treatment of other disorders are addressed in a separate paper (Part I).

show abstract

Section: Autism and Intellectual Disabilitymentioning

confidence: 99%

Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part II

Cortese,

Besag,

Clark

et al. 2024

J Psychopharmacol

View full text Add to dashboard Cite

show abstract

Time to rethink behaviours that challenge in people with intellectual disabilities

Hassiotis¹

2023

The Lancet Psychiatry

View full text Add to dashboard Cite

Gabapentin treatment for challenging behaviors in autism spectrum disorder and coexisting intellectual disability: a case report

Marini,

D'Agostino,

Ciamarra

et al. 2024

AMHID

View full text Add to dashboard Cite

Purpose The purpose of this case report is to report the clinical experience of the use of gabapentin in the management of problem behaviors in a person with autism spectrum disorder and comorbid intellectual disability. Autism spectrum disorder is a neurodevelopmental disorder with a high prevalence of intellectual disability. Challenging behaviors in autism spectrum disorder are very common. In recent years, the hypothesis that the symptoms of autism derive from a deficiency of the inhibitory neurotransmission of gamma-aminobutyric acid is gaining considerable weight. Design/methodology/approach Exploring behavioral symptoms improvement in an adult man with ASD and severe intellectual disability taking gabapentin. Findings The rating scales used show improvement in challenging behaviors and aggressions. No side effects were observed. Originality/value Currently, there are no authorized drugs for the treatment of the symptomatic features of autism spectrum disorder, but drugs are used for comorbid psychopathological aspects. The authors want to speculate on a hypothetical function of gabapentin in remodeling the expression of alpha-2-delta subunits in people with autism and the processing of neural information.

show abstract

Non-pharmacological and pharmacological interventions for the reduction or prevention of topographies of behaviours that challenge in people with intellectual disabilities: a systematic review and meta-analysis of randomised controlled trials

Cited by 7 publications

References 35 publications

Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part II

Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part II

Time to rethink behaviours that challenge in people with intellectual disabilities

Gabapentin treatment for challenging behaviors in autism spectrum disorder and coexisting intellectual disability: a case report

Contact Info

Product

Resources

About